Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs

C118P, a phosphate prodrug of C118, which is a novel microtubule protein inhibitor, is currently under Phase I clinical development in China for treating ovarian cancer and lung cancer. The preclinical pharmacokinetics of prodrug C118P and its metabolite C118 were extensively characterized in vivo i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cang, Zhang, Xiaolan, Wang, Guangji, Peng, Ying, Zhang, Xueyuan, Wu, Hui, Yu, Boyang, Sun, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278385/
https://www.ncbi.nlm.nih.gov/pubmed/30400617
http://dx.doi.org/10.3390/molecules23112883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278385/
https://www.ncbi.nlm.nih.gov/pubmed/30400617
http://dx.doi.org/10.3390/molecules23112883

Ejemplares similares